HENGRUI PHARMA (01276.HK) -1.050 (-1.683%) Short selling $39.38M; Ratio 19.628% announced that its subsidiary, Suzhou Suncadia Biopharmaceuticals, has received the Drug Clinical Trial Approval Notice for the SHR-3079 injection issued by the National Medical Products Administration, and will commence clinical trials in the near term. SHR-3079 injection is an innovative anti-tumor drug independently developed by the company, and is intended for the treatment of B-cell non-Hodgkin lymphoma. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)Related News G Sachs: Continue to Favor Visibility-led CDMO, Closely Watch Early Signs of Market Bottoming
AASTOCKS Financial News